ASCO GU Recap: Groundbreaking Studies and Exciting Developments in Genitourinary Cancers

ASCO GU Recap: Groundbreaking Studies and Exciting Developments in Genitourinary Cancers


The 2023 ASCO Genitourinary Cancers Symposium took place February 16-18, 2023, in San Francisco, California. Catch up on groundbreaking developments from the meeting on Aggrego Oncology.

  1. Atezolizumab in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Results from the Phase 3 IMvigor130 Study

Two abstracts presented at the 2023 ASCO Genitourinary Cancers Symposium shared results from the IMvigor130 study evaluating atezolizumab in the treatment of locally advanced or metastatic urothelial carcinoma (mUC). The phase 3 IMvigor trial studied atezolizumab both in combination with platinum/gemcitabine as a first-line treatment, and as a monotherapy in place of chemotherapy.

  1. Nivolumab Demonstrates Durable Clinical Success in High-Risk Muscle-Invasive Urothelial Carcinoma

Extended follow-up results from the phase 3 CheckMate 274 trial demonstrate that  nivolumab continued to improve disease-free survival (DFS), non-urothelial tract recurrence-free survival (RFS), and distant metastasis-free survival (DMFS) vs placebo in patients with high-risk muscle invasive urothelial carcinoma after radical resection.

  1. Radiolabeled 89Zr-DFO-girentuximab Demonstrates Accuracy for Identifying Clear Cell Renal Cell Carcinoma

According to findings from the ZIRCON trial, radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) PET/CT is well tolerated and can accurately and noninvasively identify clear cell renal carcinoma in imaging.

  1. Rucaparib Improves OS in Metastatic Castration-Resistant Prostate Cancer

Interim results of the phase 3 TRITON3 study demonstrated that rucaparib improved overall survival (OS) vs physician’s choice of therapy (docetaxel, abiraterone, or enzalutamide) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

  1. Darolutamide Plus ADT With Docetaxel Provides New Standard of Care for Patients With mHSPC

According to findings from the phase 3 ARASENS study, the overall survival (OS) benefits of early treatment intensification with darolutamide plus androgen-deprivation therapy among patients with metastatic hormone sensitive prostate cancer were similar regardless of whether patients had high- or low-volume, or high- or low-risk disease.


To see more of the latest conference coverage from top oncology events, sign up for an Aggrego Oncology account and have breaking news delivered to your inbox daily